Uncategorized

Press news: Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump®

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces the agreed outcome of the “Day 100” meetingi with the US Food and Drug Administration, following receipt of the “Day 90” major deficiency Letter.

Press news: Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump® Read More »

DC Medicaid Becomes the First Medicaid Plan to Cover the Nerivio® REN Wearable, a Non-Drug Treatment for Migraine

Theranica, a neuromodulation therapeutics company, today announced DC Medicaid’s coverage of the Nerivio® REN wearable, the first and only FDA-cleared, non-drug, non-disruptive treatment for both acute attacks and prevention of migraine with or without aura in adolescents and adults ages 12 and older.

DC Medicaid Becomes the First Medicaid Plan to Cover the Nerivio® REN Wearable, a Non-Drug Treatment for Migraine Read More »

Scroll to Top